Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
16 05 2019
16 05 2019
Historique:
received:
09
12
2018
accepted:
08
02
2019
pubmed:
15
2
2019
medline:
14
1
2020
entrez:
15
2
2019
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scoring systems aim to select patients for transplantation. Here, we aimed to develop a prognostic score to determine prognosis after transplantation itself, using clinical, molecular, and transplant-specific information from a total of 361 patients with myelofibrosis. Of these, 205 patients were used as a training cohort to create a clinical-molecular myelofibrosis transplant scoring system (MTSS), which was then externally validated in a cohort of 156 patients. Multivariable analysis on survival identified age at least 57 years, Karnofsky performance status lower than 90%, platelet count lower than 150 × 10
Identifiants
pubmed: 30760453
pii: S0006-4971(20)42562-5
doi: 10.1182/blood-2018-12-890889
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2233-2242Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 by The American Society of Hematology.